Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy

BACKGROUND: Depression has a lifetime prevalence of 10%–25% among women and 5%–12% among men. Selective serotonin reuptake inhibitors (SSRIs) are the most used and the most cost-effective treatment for long-term major depressive disorder. Since the introduction of generic SSRIs, the costs of branded...

Descripción completa

Detalles Bibliográficos
Autores principales: Mencacci, Claudio, Di Sciascio, Guido, Katz, Pablo, Ripellino, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570079/
https://www.ncbi.nlm.nih.gov/pubmed/23413176
http://dx.doi.org/10.2147/CEOR.S39492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570079/
https://www.ncbi.nlm.nih.gov/pubmed/23413176
http://dx.doi.org/10.2147/CEOR.S39492

Ejemplares similares